Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125031872 | 12503187 | 2 | F | 201606 | 20160706 | 20160628 | 20160708 | EXP | PHHY2016MX086921 | NOVARTIS | 76.27 | YR | F | Y | 0.00000 | 20160708 | CN | COUNTRY NOT SPECIFIED | MX |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125031872 | 12503187 | 1 | PS | EXELON PATCH | RIVASTIGMINE | 1 | Transdermal | 4.6 MG [PATCH 5(CM)2], QD | 22083 | 4.6 | MG | TRANS-THERAPEUTIC-SYSTEM | QD |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125031872 | 12503187 | 1 | Gait disturbance |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 125031872 | 12503187 | OT |
| 125031872 | 12503187 | DS |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125031872 | 12503187 | Abasia | |
| 125031872 | 12503187 | Product use issue | |
| 125031872 | 12503187 | Visual impairment |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 125031872 | 12503187 | 1 | 201606 | 0 |